Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 4/20 | 0.46 |
| ▸ | PLAU | P00749 | 4/20 | 0.46 |
| ▸ | PLAT | P00750 | 4/20 | 0.46 |
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.40 |
| ▸ | PPARA | Q07869 | 4/20 | 0.40 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215677 | 0.87 | TSHR (0.47) | PLGPLAUPLATPTGESPPARG | |
| SCHEMBL3087598 | 0.85 | PLAU (0.59) | PLGPLAUPLATPPARGPPARA | |
| SCHEMBL6218156 | 0.85 | PLG (0.48) | PLGPLAUPLATPTGESPPARG | |
| SCHEMBL8986811 | 0.84 | PLG (0.45) | PLGPLAUPLATPTGESPPARG | |
| SCHEMBL17128638 | 0.83 | ACHE (0.53) | PLGPLAUPLATPPARGPPARA | |
| SCHEMBL17128651 | 0.82 | PLG (0.43) | PLGPLAUPLATPTGESPPARG | |
| SCHEMBL14122012 | 0.81 | PPARG (0.47) | PTGESPPARGPPARAMEP1BALDH1A1 | |
| SCHEMBL3921799 | 0.80 | CYP2C9 (0.50) | PLGPLAUPTGESPPARGPPARA | |
| SCHEMBL1125437 | 0.80 | CYP2C9 (0.50) | PLGPLAUPTGESPPARGPPARA | |
| SCHEMBL3981309 | 0.80 | HSD17B10 (0.48) | PLGPLAUPLATCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | PLG 870/4885PLAU 598/4885PLAT 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.